Corcept Therapeutics Q3 Net Income $126.778 Million
Story updates
09:22:48 PM UTC
SquawkNews
Corcept Therapeutics reported third-quarter 2026 revenue of $340.47 million, up 64% from the prior-year quarter, while net income rose to $124.49 million and diluted EPS increased to $1.01. Growth reflected higher hypercortisolism sales and the launch of Lifyorli.Financial Highlights¹ Reported as “…